Menu
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Direct Line Insurance Grp.

WKN: A14USN / Name: DIRECT LINE INS / Stock / Insurance / Mid Cap /

€3.58
-1.000%

Preformed Line Products Co

WKN: A0B8P4 / Name: Preformed Line / Stock / Communications & Networking / Small Cap /

€176.00
-2.220%

Nippon Yusen K.k. (nyk Line)

WKN: A0RECG / Name: Nippon Yusen K.k. (nyk Line) / Stock / ? /

€5.40
-

Viking Line Ab

WKN: 897068 / Name: Viking Line Ab / Stock / ? /

€20.70
-2.360%

Norwegian Cruise Line Hl.

WKN: A1KBL8 / Symbol: NCLH / Name: Nrwn Crs Ln Hldg / Stock / Hotels & Entertainment Services / Large Cap /

€19.44
2.400%

Pelayaran Tempuran Emas Tbk PT

WKN: A0JJWQ / Name: Temas Line / Stock / Freight & Logistics Services / Micro Cap /

€0.005
-

Old Dominion Freight Line

WKN: 923655 / Symbol: ODFL / Name: Old Dominion / Stock / Freight & Logistics Services / Large Cap /

€135.90
-0.370%

AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer

Solid Electrolyzer Demand Drives Plug Power: Will the Momentum Last?
Solid Electrolyzer Demand Drives Plug Power: Will the Momentum Last?

Plug Power Inc. PLUG has been benefiting from robust demand for the electrolyzer product line. In the first nine months of 2025, revenues from the electrolyzer product line surged 61% on a

AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, for first-line use in breast cancer

Norwegian Cruise Line (NCLH) Outperforms Broader Market: What You Need to Know
Norwegian Cruise Line (NCLH) Outperforms Broader Market: What You Need to Know

In the latest trading session, Norwegian Cruise Line (NCLH) closed at $22.78, marking a +2.06% move from the previous day. This move outpaced the S&P 500's daily gain of 0.19%. At the same time, the

line
First extensive comment

BlackBerry's Q3 Earnings Ahead: Will QNX Emerge as Key Growth Engine?: https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg
BlackBerry's Q3 Earnings Ahead: Will QNX Emerge as Key Growth Engine?

BlackBerry Limited BB is set to report third-quarter fiscal 2026 results on Dec. 18.

The Zacks Consensus Estimate for the bottom line is pinned at 4 cents and has remained unchanged in the past 60

MTG vs. ZURVY: Which Stock Is the Better Value Option?
MTG vs. ZURVY: Which Stock Is the Better Value Option?

Investors with an interest in Insurance - Multi line stocks have likely encountered both MGIC Investment (MTG) and Zurich Insurance Group Ltd. (ZURVY). But which of these two stocks presents

Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up

Tempus AI TEM posted another breakout quarter as diagnostics volumes and pricing improved while data partnerships extended visibility. Execution on mix, reimbursement and bookings sets a clearer

NCLH's Debt Refinancing Momentum Builds: Is Balance Sheet Risk Easing?
NCLH's Debt Refinancing Momentum Builds: Is Balance Sheet Risk Easing?

Norwegian Cruise Line Holdings Ltd. NCLH continues to make measurable progress in strengthening its balance sheet, an area that has remained central to investor scrutiny since the pandemic-era

KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data: https://staticx-tuner.zacks.com/images/articles/main/45/130446.webp
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data

Shares of Kyverna Therapeutics KYTX surged 23.2% on Monday after the company reported positive top-line data from a registrational mid-stage study of its investigational candidate, mivocabtagene

AGESY or AXAHY: Which Is the Better Value Stock Right Now?
AGESY or AXAHY: Which Is the Better Value Stock Right Now?

Investors with an interest in Insurance - Multi line stocks have likely encountered both Ageas SA (AGESY) and Axa Sa (AXAHY). But which of these two stocks offers value investors a better bang for

Mission Produce Faces Headwinds Before Q4 Earnings: Buy, Hold or Sell?
Mission Produce Faces Headwinds Before Q4 Earnings: Buy, Hold or Sell?

Mission Produce Inc. AVO is likely to witness top and bottom-line declines when it reports fourth-quarter fiscal 2025 results on Dec. 18, after market close. The Zacks Consensus Estimate for fiscal

Lamb Weston Q2 Earnings on Deck: Key Factors You Should Understand
Lamb Weston Q2 Earnings on Deck: Key Factors You Should Understand

Lamb Weston Holdings, Inc. (LW) is likely to witness a top-line decline when it reports second-quarter fiscal 2026 earnings on Dec. 19. The Zacks Consensus Estimate for revenues is pegged at $1.59